transmedТрансляционная медицинаTranslational Medicine2311-44952410-5155Almazov National Medical Research Centre, Saint Petersburg, Russia10.18705/2311-4495-2019-6-3-15-24transmed-456Research ArticleСЕРДЕЧНО-СОСУДИСТЫЕ ЗАБОЛЕВАНИЯCARDIOVASCULAR MEDICINEОценка риска кардиальных событий у больных стабильной ишемической болезнью сердца после чрескожного коронарного вмешательства, сопровождающегося повреждением миокардаRisk Assessment of Cardiac Events in Patients with Stable Ischemic Heart Disease After Percutaneous Coronary Intervention, Accompanied by Myocardial DamageВоробьеваА. В.VorobyovaA. V.

Воробьева Анастасия Викторовна, кардиолог отделения кардиохирургии 

Санкт-Петербург

Vorobyova Anastasya V., MD, Cardiologist, Department of Cardio-Surgery

 Saint Petersburg

a_vorobyeva@mail.ruБондаренкоБ. Б.BondarenkoB. B.

Бондаренко Борис Борисович, д.м.н., профессор, заведующий НИЛ профилактической кардиологии 

 

Bondarenko Boris B., MD, Dr. Sc., Professor, Chief Researcher, Department of Preventive Cardiology

 Saint Petersburg

boris_bondarenko@mail.ruБартВ. А.BartV. A.

Барт Виктор Александрович, к.ф.н., заведующий НИЛ биостатистики

 

Bart Victor A., PhD, Head of the Scientifi c Laboratory of Biostatistics

 Saint Petersburg

vbartvit@mail.ruМальгинаМ. П.MalginaM. P.

Мальгина Мария Петровна, к.м.н., врач функциональной диагностики, кардиолог клиники «Скандинавия»

Санкт-Петербург

Malgina Maria P., MD, PhD, Cardiologist 

 Saint Petersburg

mariamalgina@yandex.ruДорофейковВ. В.DorofeykovV. V.

Дорофейков Владимир Владимирович, д.м.н., профессор, заведующий кафедрой биохимии НГУ им. П. Ф. Лесгарта; профессор кафедры лабораторной медицины и генетики, ФГБУ «НМИЦ им. В. А. Алмазова» Минздрава России

Санкт-Петербург

Dorofeykov Vladimir V., MD, Dr. Sc., Professor, Head of Department of Biochemistry, FSEI НЕ «Lesgaft NSU, St. Petersburg»; Department of Laboratory Medicine and Genetics, Almazov National Medical Research Centre

 Saint Petersburg

vdorofeykov@yandex.ruКулешоваЭ. В.KuleshovaE. V.

Кулешова Эльвира Владимировна, д.м.н., профессор кафедры внутренних болезней, главный научный сотрудник НИО ишемической болезни сердца

 

Kuleshova Elvira V., MD, Dr. Sc., Professor, Chief Researcher, Department of Ischemic Heart Disease

 Saint Petersburg

kuleshova@yandex.ruФедеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр имени В. А. Алмазова» Министерства здравоохранения Российской ФедерацииРоссияAlmazov National Medical Research CentreRussian FederationООО «АВА-ПЕТЕР»РоссияAVA-PETERRussian FederationФедеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр имени В. А. Алмазова» Министерства здравоохранения Российской Федерации; Федеральное государственное бюджетное образовательное учреждение высшего образования «Национальный государственный университет физической культуры, спорта и здоровья имени П. Ф. Лесгафта»РоссияAlmazov National Medical Research Centre; Federal State Budget Educational Institution of Higher Education «Lesgaft National State University of Physical Education, Sport and Health, St. Petersburg»Russian Federation201909062019631524Copyright © Воробьева А.В., Бондаренко Б.Б., Барт В.А., Мальгина М.П., Дорофейков В.В., Кулешова Э.В., 20192019Воробьева А.В., Бондаренко Б.Б., Барт В.А., Мальгина М.П., Дорофейков В.В., Кулешова Э.В.Vorobyova A.V., Bondarenko B.B., Bart V.A., Malgina M.P., Dorofeykov V.V., Kuleshova E.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://transmed.almazovcentre.ru/jour/article/view/456Актуальность

Актуальность. Чрескожное коронарное вмешательство (ЧКВ) у больных ИБС в 3–30 % случаев сопровождается повреждением миокарда с повышением содержания тропонина в сыворотке крови, однако его прогностическое значение оценивается неоднозначно.

Цель

Цель. Оценить факторы риска развития кардиальных событий в отдаленном периоде у больных стабильной ИБС с повреждением миокарда после ЧКВ.

Материалы и методы

Материалы и методы. В исследование включены 113 больных со стабильной ИБС, которым выполнено плановое ЧКВ. До и через 24 часа после вмешательства определялось содержание тропонина в сыворотке крови. Повторное обследование больных проводилось через 12–18 месяцев (в среднем 15 месяцев).

Результаты

Результаты. У 25 больных (22,2 %) после ЧКВ выявлено повышение содержания тропонина более верхнего референсного уровня, у 88 (77,8 %) признаков повреждения миокарда не было. За время наблюдения кардиальные события развились у 25,6 % больных: инфаркт миокарда у 2,6 %, рецидив стенокардии у 23 %. При однофакторном дисперсионном анализе установлено, что значимыми факторами риска кардиальных событий являются возраст, распространенность и степень стенозирования коронарных артерий, сложность стенозов и количество имплантированных стентов. Первые три из этих показателей вошли в итоговую комбинацию пошаговой процедуры дискриминантного анализа, также статистически значимую для прогноза. Дополнительно, в рамках общей линейной модели дискриминантного анализа, была установлена значимость постдилатации и перенесенного ранее инфаркта миокарда.

Заключение

Заключение. У больных стабильной ИБС, включенных в исследование, определяющими факторами риска развития кардиальных событий  явились распространенность и характер обструктивного поражения коронарного русла, возраст, перенесенный ранее инфаркт миокарда и особенности выполнения ЧКВ. Повреждение миокарда не было идентифицировано как фактор риска рецидива стенокардии или развития ИМ. 

Background

Background. Percutaneous coronary intervention (PCI) in patients with ischemic heart disease (IHD) is followed often by myocardial injury. Up to now there is no mutual agreement to the infl uence of the perioperative myocardial injury on the long-term prognosis of the IHD patients.

Objective

Objective. The aim of study was to assess the risk factors for the development of cardiac events in the long-term period in patients with stable coronary artery disease with myocardial damage after PCI.

Materials and methods

Materials and methods. The study included 113 patients with stable coronary artery disease who underwent planned PCI. Serum troponin levels were determined before and 24 hours after the intervention. Re-examination of patients was carried out after 12–18 months (average 15 months).

Results

Results. The post PCI Tn I level over a reference one was registered in 25 patients (22,2 %). During the follow-up period the cardiovascular events took place in 25,6 % patients: acute myocardial infarction (MI) in 3 (2,6 %), angina occurred in 23 %. One-way ANOVA revealed a signifi cant value for cardiac risk events of the patient age, number of stenosed arteries, summary degree of stenosis, and their complicity, number of implanted stents. The fi rst three of them were included in the fi nal combination of the stepwise discriminant analysis. The general linear model of the latter detected additionally statistical signifi cance of the variables “MI in the past” (before PCI) and “number of postdilatations“.

Conclusion

Conclusion. In patients with stable ischemic heart disease, included in the study, the determining risk factors for the development of cardiac events were the prevalence and nature of the obstructive lesion of the coronary bed, age, previous myocardial infarction, and especially the performance of PCI. Myocardial damage was not identifi ed as a risk factor for recurrent angina or myocardial infarction.

стабильная ИБСчрескожное коронарное вмешательство (ЧКВ)повреждение миокардатропонинкардиальные событияischemic heart diseasestable anginapercutaneous coronary interventionmyocardial injurytroponincardiac eventsReferencesBrener SJ, Ellis SG, Schneider J et al. Frequency and Long-Term Impact of Myonecrosis After Coronary Stenting. Eur Heart J. 2002;23(11):869–876.Brener SJ, Ellis SG, Schneider J et al. Frequency and Long-Term Impact of Myonecrosis After Coronary Stenting. Eur Heart J. 2002;23(11):869–876.Кулешова Э.В., Дорофейков В.В., Воробьева А.В. и др Микроповреждения миокарда при коронарной баллонной ангиопластике (обзор литературы). Артериальная гипертензия 2010;16(6):535–541.Kuleshova EV, Dorofeykov VV, Vorobyova AV et al. Myocardium Microlesions in Percutaneous Coronary Angioplasty (Review).Arterial’naya Gipertenziya = Arterial Hypertension. 2010;16(6):535–541. In RussianWang TY, Peterson ED, Dai D et al. Patterns of Cardiac Marker Surveillance After Elective Percutaneous Coronary Intervention and Implications for the Use of Periprocedural Myocardial Infarction as a Quality Metric: A Report from the National Cardiovascular Data Registry (NCDR). J Am Coll Cardiol. 2008;51(21):2068–2074.Wang TY, Peterson ED, Dai D et al. Patterns of Cardiac Marker Surveillance After Elective Percutaneous Coronary Intervention and Implications for the Use of Periprocedural Myocardial Infarction as a Quality Metric: A Report from the National Cardiovascular Data Registry (NCDR). J Am Coll Cardiol. 2008;51(21):2068–2074.Jaffe R, Charron T, Puley G et al. Microvascular Obstruction and the No-Refl ow Phenomenon After Percutaneous Coronary Intervention. Circulation. 2008;117(24): 3152–3156.Jaffe R, Charron T, Puley G et al. Microvascular Obstruction and the No-Refl ow Phenomenon After Percutaneous Coronary Intervention. Circulation. 2008;117(24): 3152–3156.Дорофейков В.В., Кулешова Э.В., Воробьева А.В. и др. Лабораторная диагностика микроповреждений миокарда во время коронарной баллонной ангиопластики со стентированием. Клиническая лабораторная диагностика. 2011;2:15–18.Dorofeikov VV, Kuleshova EV, Vorobyeva AV et al. Laboratory Diagnosis of Myocardial Microlesions During Coronary Balloon Angioplasty with Stenting. Klinicheskaya laboratornaya diagnostika = Clinical laboratory diagnostics. 2011;2:15–18. In RussianВоробьева А.В., Бондаренко Б.Б., Барт В.А., и др. О факторах повреждения миокарда при плановом чрескожном коронарном вмешательстве. Вестник Санкт-Петербургского университета. Медицина. 2014; 1:168–179.Vorobyova AV, Bondarenko BB, Bart VA et al. On the Factors for Periprocedure Myocardial Injury. Vestnik Sankt-Peterburgskogo universiteta. Medicina = Bulletin of St. Petersburg University. Medicine. 2014;1:168–179. In RussianButurak A, Degirmencioglu A, Surgit O et al. Rise of Serum Troponin Levels Following Uncomplicated Elective Percutaneous Coronary Interventions in Patients Without Clinical and Procedural Signs Suggestive of Myocardial Necrosis. Postepy Kardiol Interwencyjnej. 2016;12(1):41–48.Buturak A, Degirmencioglu A, Surgit O et al. Rise of Serum Troponin Levels Following Uncomplicated Elective Percutaneous Coronary Interventions in Patients Without Clinical and Procedural Signs Suggestive of Myocardial Necrosis. Postepy Kardiol Interwencyjnej. 2016;12(1):41–48.Thygesen K, Alpert JS, Jaffe AS, et al, Executive Group on Behalf of the Joint European Society of Cardiology (ESC)/American College of Cardiology (ACC)/American Heart Association (AHA)/World Heart Federation (WHF) Task Force for the Universal Definition of Myocardial Infarction. Fourth Universal Defi nition of Myocardial Infarction (2018). Glob Heart. 2018;13(4):305–338.Thygesen K, Alpert JS, Jaffe AS, et al, Executive Group on Behalf of the Joint European Society of Cardiology (ESC)/American College of Cardiology (ACC)/American Heart Association (AHA)/World Heart Federation (WHF) Task Force for the Universal Definition of Myocardial Infarction. Fourth Universal Defi nition of Myocardial Infarction (2018). Glob Heart. 2018;13(4):305–338.Feldman DN, Kim L, Rene AG et al. Prognostic Value of Cardiac Troponin-I or Troponin-T Elevation Following Nonemergent Percutaneous Coronary Intervention: A Meta-Analysis. Catheter Cardiovasc Interv. 2011;77(7): 1020–1030.Feldman DN, Kim L, Rene AG et al. Prognostic Value of Cardiac Troponin-I or Troponin-T Elevation Following Nonemergent Percutaneous Coronary Intervention: A Meta-Analysis. Catheter Cardiovasc Interv. 2011;77(7): 1020–1030.Omland T, Pfeffer MA, Solomon SD et al. Prognostic Value of Cardiac Troponin I Measured with a Highly Sensitive Assay in Patients with Stable Coronary Artery Disease. J Am Coll Cardiol. 2013;61(12):1240–1249.Omland T, Pfeffer MA, Solomon SD et al. Prognostic Value of Cardiac Troponin I Measured with a Highly Sensitive Assay in Patients with Stable Coronary Artery Disease. J Am Coll Cardiol. 2013;61(12):1240–1249.Everett BM, Brooks MM, Vlachos HE et al. Troponin and Cardiac Events in Stable Ischemic Heart Disease and Diabetes. N Engl J Med. 2015;373(7):610–620.Everett BM, Brooks MM, Vlachos HE et al. Troponin and Cardiac Events in Stable Ischemic Heart Disease and Diabetes. N Engl J Med. 2015;373(7):610–620.Zeitouni M, Silvain J, Guedeney P et al. Periprocedural Myocardial Infarction and Injury in Elective Coronary Stenting. Eur Heart J. 2018;39(13):1100–1109.Zeitouni M, Silvain J, Guedeney P et al. Periprocedural Myocardial Infarction and Injury in Elective Coronary Stenting. Eur Heart J. 2018;39(13):1100–1109.Holmes DR Jr, Berger PB. Troponisms, Necrosettes, Enzyme Leaks, Creatinine Phosphokinase Bumps, and Infarctlets: What’s Behind This New Lexicon and What Does It Add? Circulation. 2001;104(6):627–629.Holmes DR Jr, Berger PB. Troponisms, Necrosettes, Enzyme Leaks, Creatinine Phosphokinase Bumps, and Infarctlets: What’s Behind This New Lexicon and What Does It Add? Circulation. 2001;104(6):627–629.White HD. Pathobiology of Troponin Elevations: Do Elevations Occur with Myocardial Ischemia As Well As Necrosis? J Am Coll Cardiol. 2011;57(24):2406–2408.White HD. Pathobiology of Troponin Elevations: Do Elevations Occur with Myocardial Ischemia As Well As Necrosis? J Am Coll Cardiol. 2011;57(24):2406–2408.Zhang M, He H, Wang ZM et al. Diagnostic and Prognostic Value of Minor Elevated Cardiac Troponin Levels for Percutaneous Coronary Intervention-Related Myocardial Injury: A Prospective, Single-Center and Double-Blind Study. J Biomed Res. 2014;28(2):98–107.Zhang M, He H, Wang ZM et al. Diagnostic and Prognostic Value of Minor Elevated Cardiac Troponin Levels for Percutaneous Coronary Intervention-Related Myocardial Injury: A Prospective, Single-Center and Double-Blind Study. J Biomed Res. 2014;28(2):98–107.Ndrepepa G, Colleran R, Braun S et al. High-Sensitivity Troponin T and Mortality After Elective Percutaneous Coronary Intervention. J Am Coll Cardiol. 2016;68(21): 2259–2268.Ndrepepa G, Colleran R, Braun S et al. High-Sensitivity Troponin T and Mortality After Elective Percutaneous Coronary Intervention. J Am Coll Cardiol. 2016;68(21): 2259–2268.Миронова О. Ю. Повышение маркеров некроза миокарда вследствие проведения плановой ангиопластики коронарных артерий и однолетний прогноз. Кардиологический вестник. 2015; 10 (1): 58–67.Mironova OY. The Rise of Cardiac Biomarkers Due to Planned PCI and 1-Year Prognosis. Kardiologicheskij vestnik = Cardiological Bulletin. 2015;10(1):58–67. In RussianОрлова А.Ф., Лейтес И.В., Черникова И.В. Пробы с физической нагрузкой. Методическое пособие по велоэргометрии. Барнаул, 2002.с.37.Orlova AF, Lejtes IV, Chernikova IV. Toolkit for Veloergometry. Barnaul, 2002.p.37. In RussianWindecker S, Kolh P, Alfonso F et al. 2014 ESC/ EACTS Guidelines on Myocardial Revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the Special Contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014;35(37):2541–2619.Windecker S, Kolh P, Alfonso F et al. 2014 ESC/ EACTS Guidelines on Myocardial Revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the Special Contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014;35(37):2541–2619.Guidelines for Percutaneous Transluminal Coronary Angioplasty. A Report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee on Percutaneous Transluminal Coronary Angioplasty). J Am Coll Cardiol. 1988;12(2):529–545.Guidelines for Percutaneous Transluminal Coronary Angioplasty. A Report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee on Percutaneous Transluminal Coronary Angioplasty). J Am Coll Cardiol. 1988;12(2):529–545.Farooq V, Vergouwe Y, Räber L et al. Combined Anatomical and Clinical Factors for the Long-Term Risk Stratifi cation of Patients Undergoing Percutaneous Coronary Intervention: The Logistic Clinical SYNTAX Score. Eur Heart J. 2012;33(24):3098–3104.Farooq V, Vergouwe Y, Räber L et al. Combined Anatomical and Clinical Factors for the Long-Term Risk Stratifi cation of Patients Undergoing Percutaneous Coronary Intervention: The Logistic Clinical SYNTAX Score. Eur Heart J. 2012;33(24):3098–3104.Fitzgibbon GM, Burggraf GW, Groves TD et al. A Double Master’s Two-Step Test: Clinical, Angiographic and Hemodynamic Correlation. Ann Intern Med. 1971; 74 (4): 509–517.Fitzgibbon GM, Burggraf GW, Groves TD et al. A Double Master’s Two-Step Test: Clinical, Angiographic and Hemodynamic Correlation. Ann Intern Med. 1971; 74 (4): 509–517.Nienhuis MB, Ottervanger JP, Bilo HJ et al. Prognostic Value of Troponin After Elective Percutaneous Coronary Intervention: A Meta-Analysis. Catheter Cardiovasc Interv. 2008;71(3):318–324.Nienhuis MB, Ottervanger JP, Bilo HJ et al. Prognostic Value of Troponin After Elective Percutaneous Coronary Intervention: A Meta-Analysis. Catheter Cardiovasc Interv. 2008;71(3):318–324.De Labriolle A, Lemesle G, Bonello L et al. Prognostic Signifi cance of Small Troponin I Rise After a Successful Elective Percutaneous Coronary Intervention of a Native Artery. Am J Cardiol. 2009;103(5):639–645.De Labriolle A, Lemesle G, Bonello L et al. Prognostic Signifi cance of Small Troponin I Rise After a Successful Elective Percutaneous Coronary Intervention of a Native Artery. Am J Cardiol. 2009;103(5):639–645.Testa L, Van Gaal WJ, Biondi Zoccai GG et al. Myocardial Infarction After Percutaneous Coronary Intervention: A Meta-Analysis of Troponin Elevation Applying the New Universal Defi nition. QJM. 2009;102(6):369–378.Testa L, Van Gaal WJ, Biondi Zoccai GG et al. Myocardial Infarction After Percutaneous Coronary Intervention: A Meta-Analysis of Troponin Elevation Applying the New Universal Defi nition. QJM. 2009;102(6):369–378.Kini AS, Lee P, Marmur JD et al. Correlation of Postpercutaneous Coronary Intervention Creatine KinaseMB and Troponin I Elevation in Predicting Mid-Term Mortality. Am J Cardiol. 2004;93(1):18 –23.Kini AS, Lee P, Marmur JD et al. Correlation of Postpercutaneous Coronary Intervention Creatine KinaseMB and Troponin I Elevation in Predicting Mid-Term Mortality. Am J Cardiol. 2004;93(1):18 –23.Zimarino M, Cicchitti V, Genovesi E et al. Isolated Troponin Increase After Percutaneous Coronary Interventions: Does It Have Prognostic Relevance? Atherosclerosis. 2012;221(2):297–302.Zimarino M, Cicchitti V, Genovesi E et al. Isolated Troponin Increase After Percutaneous Coronary Interventions: Does It Have Prognostic Relevance? Atherosclerosis. 2012;221(2):297–302.Hubacek J, Basran RS, Shrive FM et al. Prognostic Implications of C-Reactive Protein and Troponin Following Percutaneous Coronary Intervention. Can J Cardiol. 2009; 25(2):e42–e47.Hubacek J, Basran RS, Shrive FM et al. Prognostic Implications of C-Reactive Protein and Troponin Following Percutaneous Coronary Intervention. Can J Cardiol. 2009; 25(2):e42–e47.Frӧhlich GM, Leistner DM. The Relevance of Periprocedural Troponin Rise: The Never Ending Story! Open Heart. 2017;4(2):e000590.Frӧhlich GM, Leistner DM. The Relevance of Periprocedural Troponin Rise: The Never Ending Story! Open Heart. 2017;4(2):e000590.Coronary Angioplasty Versus Medical Therapy for Angina: The Second Randomised Intervention Treatment of Angina (RITA-2) Trial. RITA-2 Trial Participants. Lancet. 1997; 350(9076):461–468.Coronary Angioplasty Versus Medical Therapy for Angina: The Second Randomised Intervention Treatment of Angina (RITA-2) Trial. RITA-2 Trial Participants. Lancet. 1997; 350(9076):461–468.Serruys PW, Unger F, Sousa JE et al. Comparison of Coronary-Artery Bypass Surgery and Stenting for the Treatment of Multivessel Disease. N Engl J Med. 2001; 344(15): 1117–1124.Serruys PW, Unger F, Sousa JE et al. Comparison of Coronary-Artery Bypass Surgery and Stenting for the Treatment of Multivessel Disease. N Engl J Med. 2001; 344(15): 1117–1124.Holubkov R, Laskey WK, Haviland A et al. Angina 1 Year After Percutaneous Coronary Intervention: A Report from the NHLBI Dynamic Registry. Am Heart J. 2002;144(5):826–833.Holubkov R, Laskey WK, Haviland A et al. Angina 1 Year After Percutaneous Coronary Intervention: A Report from the NHLBI Dynamic Registry. Am Heart J. 2002;144(5):826–833.Henderson RA, Pocock SJ, Clayton TC et al. Seven-Year Outcome in the RITA-2 Trial: Coronary Angioplasty Versus Medical Therapy. J Am Coll Cardiol. 2003; 42(7):1161–1170.Henderson RA, Pocock SJ, Clayton TC et al. Seven-Year Outcome in the RITA-2 Trial: Coronary Angioplasty Versus Medical Therapy. J Am Coll Cardiol. 2003; 42(7):1161–1170.Shah BR, Cowper PA, O’Brien SM et al. Patterns of Cardiac Stress Testing After Revascularization in Community Practice. J Am Coll Cardiol. 2010;56(16):1328–1334.Shah BR, Cowper PA, O’Brien SM et al. Patterns of Cardiac Stress Testing After Revascularization in Community Practice. J Am Coll Cardiol. 2010;56(16):1328–1334.Tavella R, Ranasinghe I, Zeitz C et al. Post-Percutaneous Coronary Intervention Angina: A New Performance Measure? JACC Cardiovasc Interv. 2015;8(12):1639–1640.Tavella R, Ranasinghe I, Zeitz C et al. Post-Percutaneous Coronary Intervention Angina: A New Performance Measure? JACC Cardiovasc Interv. 2015;8(12):1639–1640.Serruys PW, Chevalier B, Sotomi Y et al. Comparison of an Everolimus-Eluting Bioresorbable Scaffold with an Everolimus-Eluting Metallic Stent for the Treatment of Coronary Artery Stenosis (ABSORB II): A 3 Year, Randomised, Controlled, Single-Blind, Multicentre Clinical Trial. Lancet. 2016;388(10059):2479–2491.Serruys PW, Chevalier B, Sotomi Y et al. Comparison of an Everolimus-Eluting Bioresorbable Scaffold with an Everolimus-Eluting Metallic Stent for the Treatment of Coronary Artery Stenosis (ABSORB II): A 3 Year, Randomised, Controlled, Single-Blind, Multicentre Clinical Trial. Lancet. 2016;388(10059):2479–2491.Stone GW, Ellis SG, Gori T et al. Blinded Outcomes and Angina Assessment of Coronary Bioresorbable Scaffolds: 30-Day and 1-Year Results from the ABSORB IV Randomised Trial. Lancet. 2018;392(10157):1530–1540.Stone GW, Ellis SG, Gori T et al. Blinded Outcomes and Angina Assessment of Coronary Bioresorbable Scaffolds: 30-Day and 1-Year Results from the ABSORB IV Randomised Trial. Lancet. 2018;392(10157):1530–1540.Neumann FJ, Sousa-Uva M, Ahlsson A et al. 2018 ESC/EACTS Guidelines on Myocardial Revascularization. Eur Heart J. 2019;40(2):87–165.Neumann FJ, Sousa-Uva M, Ahlsson A et al. 2018 ESC/EACTS Guidelines on Myocardial Revascularization. Eur Heart J. 2019;40(2):87–165.Al-Lamee R, Thompson D, Dehbi HM et al. Percutaneous Coronary Intervention in Stable Angina (ORBITA): A Double-Blind, Eandomised Controlled Trial. Lancet. 2018;391(10115):31–40.Al-Lamee R, Thompson D, Dehbi HM et al. Percutaneous Coronary Intervention in Stable Angina (ORBITA): A Double-Blind, Eandomised Controlled Trial. Lancet. 2018;391(10115):31–40.Tsunoda R, Sakamoto T, Kojima S et al. Recurrence of Angina Pectoris After Percutaneous Coronary Intervention Is Reduced By Statins in Japanese Patients. J Cardiol. 2011;58(3):208–215.Tsunoda R, Sakamoto T, Kojima S et al. Recurrence of Angina Pectoris After Percutaneous Coronary Intervention Is Reduced By Statins in Japanese Patients. J Cardiol. 2011;58(3):208–215.

The authors declare that there are no conflicts of interest present.